ArticleBMC nephrology2025
The carbonic anhydrase 3 protein in urine: a potential biomarker to monitor atherosclerotic renal artery stenosis.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combined Fibrinogen and Urinary α1-Microglobulin as Predictors of Respiratory Tract Infection in Children with Nephrotic Syndrome.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAtherosclerotic renal artery stenosis (ARAS) represents the predominant etiology of renal artery stenosis. Current diagnostic modalities—including renal arteriography, Doppler ultrasonography (DUS), computed tomography angiography (CTA), and magnetic resonance angiography (MRA)—are limited by invasiveness or technical constraints. The development of noninvasive biomarkers for ARAS detection is therefore clinically imperative. We hypothesize that ischemic renal injury in ARAS induces pathological alterations that generate unique urinary protein signatures.
methodsA total of 138 subjects were enrolled and randomly divided into the discovery cohort and the validation cohort. Urinary proteins from the discovery cohort were profiled using data-independent acquisition mass spectrometry (DIA-MS) to identify differentially expressed proteins. Candidate biomarkers were subsequently validated in the validation cohort via quantitative ELISA. Diagnostic performance was assessed by receiver operating characteristic (ROC) curve analysis, and associations between target protein levels and clinical parameters were evaluated using Spearman correlation.
resultsAs a result of DIA-MS indicated in the discovery cohort, 485 up-regulated urinary proteins and 177 down-regulated urinary proteins were identified in ARAS patients compared to disease controls. The top three proteins CA3, ORM2, and ART3 in AUC were selected as the potential urinary markers for further validation in the validation cohort. The uCA3/Cr level was significantly higher in both ARAS and disease controls than in healthy controls, and the uCA3/Cr level in patients with ARAS was significantly higher than in disease controls. There was no statistical difference in the uCA3/Cr level in subgroups with different severity of ARAS. Taking healthy controls as control values, the ROC area of uCA3/Cr was 0.9649(95%CI: 0.9200-1.000). We evaluated the area under the uCA3/Cr curve with the values of the disease control group as the control, the areas of ROC were 0.7391(95%CI: 0.6154–0.8628). Correlation analysis demonstrated that there was a strong positive correlation between uCA3/Cr concentration and urinary a1-microglobulin(a1MG) in ARAS and disease controls.
conclusionCA3 in urine may be related to renal interstitial injury, it could be used as a non-invasive biomarker for ARAS. However, large cohort studies and mechanistic investigations are required for further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.